Forward-Looking Statements
Some of the statements included in this web site contain forward-looking statements within the meaning of Section 27A of the Securities Act, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, that are subject to risks and uncertainties. All statements other than statements of historical facts contained on this Website including statements regarding our financial condition, operations, plans, objectives, goals, business strategies, future events, capital expenditures, future results, competitive strengths, and the trends in our industry are forward-looking statements. The words “believe,” “may,” “could,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “appear,” “forecast,” “future,” “likely,” “probably,” “suggest” “goals,” “objectives” and similar expressions, as they relate to PolyMedix, are intended to identify forward-looking statements.
Forward-looking statements reflect only our current expectations. In any forward-looking statement, where we express an expectation or belief as to future results or events, such expectation or belief is expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the statement of expectation or belief will be achieved or accomplished. Our actual results, performance or achievements could differ materially from those expressed in, or implied by, the forward-looking statements due to a number of uncertainties, many of which are unforeseen, including:
- our need for, and the availability of, substantial capital in the future to fund our operations and planned clinical trials;
- the conditions in the capital markets and the biopharmaceutical industry that make raising capital or entering into strategic arrangements difficult and expensive
- the timing of our product development and evaluation;
- the timing and magnitude of expenditures we may incur in connection with our ongoing research and development activities;
- the results of our preclinical and clinical trials, including regulatory approvals necessary for advancement and continuation of our development programs;
- the maintenance of our existing licenses with the University of Pennsylvania (Penn) and the University of Massachusetts (UMass);
- the size of the market opportunity for our product candidates;
- the success, timing and financial consequences of our formation of new business relationships and alliances; and
- the timing and volume of sales of products for which we obtain marketing approval.
PolyMedix’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties such as those set forth in our reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and Exchange Commission ("SEC").
We urge you to carefully review and consider the disclosures found in these SEC filings, all of which are available through this Website and at the SEC’s website located at www.sec.gov. Given the uncertainties affecting pharmaceutical companies in the development stage, you are cautioned not to place undue reliance on any such forward-looking statements, any of which may turn out to be wrong due to inaccurate assumptions, unknown risks, uncertainties or other factors. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. All subsequent written and oral forward looking statements attributable to us or the persons acting on our behalf are expressly qualified in their entirety by the applicable cautionary statements. PolyMedix undertakes no obligation to (and expressly disclaims any such obligation to) publicly update or revise the statements made herein or the risk factors that may relate thereto whether as a result of new information, future events or otherwise.